Merck serono : l'industrie pharmaceutique

Disponible uniquement sur Etudier
  • Pages : 16 (3792 mots )
  • Téléchargement(s) : 0
  • Publié le : 18 octobre 2010
Lire le document complet
Aperçu du document
The pharma business and how to cope with uncertainty

Riccardo Lampariello, MSc, MBA Associate Director - Portfolio Management SKEMA Business School- Paris 5 Oct 2010

POKER • 5 cards randomly drawn from a full deck of 32 • What is the probability of three of a kind at the opening?

• 5.3%.

2

R Lampariello - MerckSerono - Paris, 5 Oct 2010

Summary
High uncertainty in the pharmabusiness Merck Serono International Evaluation of R&D projects
– NPV – Dynamics of NPV: uses, abuses and misuses

Copying with project uncertainty Copying with portfolio uncertainty Conclusions

3

R Lampariello - MerckSerono - Paris, 5 Oct 2010

The pharma business

High uncertain business
Main causes of uncertainty
– Risk nature
• • • • Technical Operational Commercial MarketAccess

– Long-term results

5

R Lampariello - MerckSerono - Paris, 5 Oct 2010

Clinical drug development pipeline

5%
6 R Lampariello - MerckSerono - Paris, 5 Oct 2010

Technical risks

Source: PhRMA,2008 - Paris, 5 Oct 2010 7 R Lampariello - MerckSerono

Operational risks
R&D expenses vs. NME output(1)

70 60
Global R&D expenditure [Bn EUR] # NME approvals (FDA)

60 50 4030 20 10 0 2007e 1980 1983 1986 1989 1992 1995 1998 2001 2004

50 40 30 20 10 0

R&D expenditure

NME approvals

(1)
8

Parexel Bio/Pharmaceutical R&D Statistical Sourcebook 2006/2007
R Lampariello - MerckSerono - Paris, 5 Oct 2010

Commercial risk: will be a new world order?

(market size: value of sales)

Source: IMS, 2010
9 R Lampariello - MerckSerono - Paris, 5 Oct 2010 Reimbursement for prescribed medicines?
The global recession is exerting pressure on consumers’ and governments’ spending Gross Domestic Product Indices of Major Market Economies

10

R Lampariello - MerckSerono - Paris, 5 Oct 2010

Source: Burrill & Co and IMS Health analysis, 2009

Merck Serono: company profile
“We will create an innovative, successful pharmaceuticals business withglobal reach by leveraging our core strengths. We want to build a company being recognized as “best pharma.” Our success will benefit patients and reward employees and owners.’’ Elmar Schnee, MerckSerono President

Merck Serono Headquarters, Geneva, Switzerland

12

R Lampariello - MerckSerono - Paris, 5 Oct 2010

Merck Serono is Merck’s largest division

Merck Group
PharmaceuticalsChemicals

Merck Serono Consumer Health Care

Merck Millipore Performance Materials

Central functions

13

R Lampariello - MerckSerono - Paris, 5 Oct 2010

Divisions

Key facts & figures
Largest division of Merck KGaA Established: Business: Employees: President: Total revenues: Headquarters: Key growth drivers: January 5, 2007 Innovative small molecules & biopharmaceuticals ~17,000Elmar Schnee € 5.3 billion in 2009 Geneva, Switzerland

14

R Lampariello - MerckSerono - Paris, 5 Oct 2010

WHO WE ARE

Focused on specialist therapeutic areas
Merck Serono

Oncology

Autoimmune & Inflammatory Diseases (AIID)

Neurodegenerative Diseases

Fertility Endocrinology
15 R Lampariello - MerckSerono - Paris, 5 Oct 2010

Cardio Metabolic Care

WHO WE ARE

Salesby region

16

R Lampariello - MerckSerono - Paris, 5 Oct 2010

Our group: Merck KGaA
Merck manages its operating activities under the umbrella of Merck KGaA, Darmstadt, Germany
– Listed on the Frankfurt Stock Exchange since 1995 and included in the DAX® 30 index since June 2007 – Around 30% of the total capital is publicly traded – The Merck family, as general partner, indirectly holdsapproximately 70% of the capital

Merck operates in two main business sectors: Pharmaceuticals and Chemicals

The Pützer Tower and Pyramid at Darmstadt headquarters
17 R Lampariello - MerckSerono - Paris, 5 Oct 2010

Merck Serono Portfolio
Aug 5, 2010
Phase I
ATX-MS-1467, immune tolerizing agent Relapsing Forms of MS MEK inhibitor (AS703026) Solid tumors and hematological malignancies...
tracking img